Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103692 | 1.00 | HTR2C (0.38) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL15399575 | 1.00 | HTR2C (0.38) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL5045861 | 1.00 | HTR2C (0.38) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL16751015 | 0.82 | HTR2C (0.37) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL5493081 | 0.82 | VNN1 (0.39) | — | |
| SCHEMBL18478944 | 0.82 | HTR2C (0.37) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL14040599 | 0.82 | HTR2C (0.37) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL13379873 | 0.82 | HTR2C (0.37) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL16750117 | 0.77 | PIK3CD (0.42) | HTR2CCNR2JAK2JAK1LRRK2 | |
| SCHEMBL22802654 | 0.77 | CHRNB2 (0.38) | HTR2CCNR2JAK2JAK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | HTR2C 296/4885CNR2 16/4885JAK2 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.